原材料、当期純利益、投資有価証券評価損他1件
- 【期間】
| 年度 | 原材料 | 当期純利益 | 投資有価証券評価損 | 減価償却費 - 医薬品 |
|---|
| 2008/03 | 84百万 | | - | | - | | - | |
| 2009/03 | - | | - | | 51百万 | | - | |
| 2011/03 | - | | 24.5億 | | - | | - | |
| 2012/03 | - | | 32.7億 | +33.4% | - | | - | |
| 2013/03 | - | | 32.6億 | -0.4% | - | | 20.2億 | |
| 2014/03 | - | | 47.5億 | +45.7% | - | | 16.6億 | -17.8% |
| 2015/03 | - | | 36.5億 | -23.1% | - | | 24.9億 | +49.8% |
| 2016/03 | - | | 25.8億 | -29.4% | - | | 30.5億 | +22.5% |
| 2017/03 | - | | 17.9億 | -30.7% | - | | 27.8億 | -8.7% |
| 2018/03 | - | | 39.2億 | +119.5% | - | | 27.7億 | -0.5% |
| 2019/03 | - | | 22.4億 | -42.8% | - | | 27.5億 | -0.4% |
| 2020/03 | - | | -108億 | 赤転 | - | | 16.1億 | -41.6% |
| 2021/03 | - | | 42.6億 | 黒転 | - | | 5.32億 | -66.9% |
| 2022/03 | - | | 37.3億 | -12.4% | - | | 6.52億 | +22.6% |
| 2023/03 | - | | 22.4億 | -40.1% | - | | 8.51億 | +30.5% |
| 2024/03 | - | | 21.9億 | -2.2% | - | | 10.6億 | +24% |
